These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29930727)

  • 1. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
    Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
    Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
    Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
    Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
    Suwaki N; Vanhecke E; Atkins KM; Graf M; Swabey K; Huang P; Schraml P; Moch H; Cassidy AM; Brewer D; Al-Lazikani B; Workman P; De-Bono J; Kaye SB; Larkin J; Gore ME; Sawyers CL; Nelson P; Beer TM; Geng H; Gao L; Qian DZ; Alumkal JJ; Thomas G; Thomas GV
    Sci Transl Med; 2011 Jun; 3(85):85ra47. PubMed ID: 21632985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
    Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
    Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP.
    Liu S; Yang Y; Wang W; Pan X
    J Cell Biochem; 2018 Dec; 119(12):9694-9706. PubMed ID: 30132963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
    Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
    J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
    Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
    Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
    Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
    Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
    Orive-Ramos A; Seoane S; Ocaña A; Pandiella A; Montero JC
    Mol Oncol; 2017 Dec; 11(12):1788-1805. PubMed ID: 29032615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
    Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
    EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
    Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
    Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
    Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy.
    Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
    Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.